Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) attributable profit rose 25% to 764.8 million yuan in the first quarter from 609.7 million yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share at the drug company increased 26% to 0.29 yuan from 0.23 yuanin the year-ago period.
Operating income declined 7.3% to 9.42 billion yuan from 10.2 billion yuan in the prior-year period.
Shares slipped 4% in Hong Kong during afternoon trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。